Mainstay Medical still hopes for US approval of its Reactiv8 device for chronic back pain despite trial failure.
Smaller medtechs saw impressive share price growth in 2018, but not quite as good as the year before.
Big cap medtech disappoints – but still beats pharma.
GE arrives to the spin-out party fashionably late.
Battle of the algorithms.
Can a device control a patient’s blood sugar based on bodyweight alone?
Cracking the cancer code.
Wright's bone filler sales are growing fast, but Medtronic still rules.
It's a start, but sham-controlled trials are needed.